posted
Hard to Treat Diseases Incorporated – HTTD – Announces: Letter to the Shareholders
Delray Beach, Fla., October 6, 2005 – Hard to Treat Diseases Incorporated (HTTD) (Pink Sheets: HTDS)
A Letter from Hard to Treat Diseases, Incorporated
This letter is an opportunity to address the current status of the Company. Topics of concern and areas of importance are addressed below.
LITIGATION UPDATE:
The Federal Court issued its Memorandum Opinion on July 8, 2005. The Company’s attorneys have filed a Notice of Appeal and briefs will be posted on the Company’s website as soon as they are available. The Company does not feel the opinion reflects the evidence presented at trial.
In Oklahoma court, Shinn Capital Group, Inc. is attempting to obtain the Company’s Tubercin samples, test reports, studies, lab notes, and protocols regarding studies related to Tubercin. The Tubercin that the Company possesses is an asset of the Company. The test results and data are a result of agreements entered into by the Company and paid for by the Company. These assets belong to the Company and Shinn Capital Group, Inc. has no right to any of them.
TUBERCIN:
The Company has been in contact with Dr. Chung in South Korea. Mr. King was invited by Dr. Chung to meet with him with Ronald Shinn present. The meeting was to take place during the month of September, but as of yet no date has been set. Mr. King’s intentions are to present Dr. Chung with the extensive testing results done on Tubercin and the Company’s potential of moving his drug forward.
PROVISIONAL PATENT APPLICATION:
The Company’s application for the treatment of viral infections is a result of testing performed on a substance from Japan which the company possesses. The Company has been negotiating with a major drug firm in order to move the substance forward. The name of the substance and the drug firm will remain confidential until further negotiations are finalized.
RECYCLING PATENTS:
The Company owns 20% of International Foam Solutions, Inc., a Nevada corporation. The Company has recently discovered that the recycling patents in the names of Harvey Katz and Claudia Iovino are to be assigned to HTTD per employment agreements, SEC filings and USPTO (US Patent and Trademark Office) applications. Numerous attempts have been made to have the patents assigned to the Company. HTTD has formally notified the USPTO of the facts. In addition, the Company is in the process of formally notifying all parties that Katz has been attempting to do business with.
SECURITIES AND EXCHANGE COMMISSION (SEC):
Mr. King initiated a meeting with the enforcement division of the SEC in an attempt to protect the HTTD shareholders and investors. The Federal judge ruled that Ronald Shinn and Gerry Knight misled investors. Ronald Shinn issued 135 million shares of HTTD stock to Harvey Katz and his associates. It is believed by the Company that these shares were fraudulently issued and converted to free trading shares based on misrepresentations and fraudulent documents supplied by Harvey Katz. In addition to court documents, Mr. King has supplied the SEC with additional information and documents supporting the securities fraud.
Mr. King is in the process of supplying the SEC with all documents supporting the claim that the recycling patents are to be assigned to HTTD for the benefit of the shareholders.
CONCLUSION:
HTTD will continue to protect the interests of its shareholders by attempting to secure the rights to Tubercin, continuing the advancement of the Provisional Patent, finalizing a deal with a major drug firm and exploring the best option for our recycling division. Shareholders will be updated as developments occur.
Feel free to contact me if you have any questions or concerns.
Colm J. King, CEO Hard to Treat Diseases, Incorporated (561) 278-7856 www.htdsotc.com
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
posted
Status of Colorado & Oklahoma Replevin Actions
DELRAY BEACH, FL--(MARKET WIRE)--Nov 3, 2005 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces Colorado Judge grants HTTD's Motion to Intervene in Denver case, Denver testing entities file Motions to Dismiss case and Shinn Capital is unsuccessful in acquiring HTTD's Tubercin and testing results at yesterday's court hearing in Denver.
HTTD's assets include Tubercin and testing results from Denver and Oklahoma, resulting from agreements for testing entered into and paid for by HTTD. Shinn Capital has possessed a license agreement to market Tubercin for over five years and accomplished nothing: it has no Tubercin, no testing results and no credibility.
HTTD's CEO Colm King states, "If Shinn wants testing results, he should find a testing facility willing to perform work for him and expect to pay for results. HTTD is not willing to share its valuable results with misleading non-performers."
All motions and court documents will be posted on the Company's website at: www.htdsotc.com as soon as possible. Mr. King will also attend the Oklahoma replevin hearing scheduled for next Thursday, November 10. Shareholders will be informed on the outcome.
HTTD is moving forward on all fronts; securing rights to Tubercin, advancing our provisional patent for the treatment of viral infections and the assignment of various recycling patents to the Company.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Contact:
CONTACT Colm J. King, CEO Hard to Treat Diseases, Incorporated (561) 278-7856 http://www.htdsotc.com
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
posted
Hard to Treat Diseases, Incorporated Announces: Appellees' Cross-Appeal Dismissed by U.S. Court of Appeals Wednesday December 7, 10:59 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Dec 7, 2005 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that on December 2, 2005 the U.S. Court of Appeals dismissed the cross-appeal by Shinn Capital Group, Inc., Shinn and Knight for lack of jurisdiction. The complete text of the dismissal will be posted on HTTD's website as soon as it's available. HTTD's briefs relating to the appeal are due by December 28, 2005. The briefs will be filed with the U.S. Court of Appeals prior to the due date and will be posted on the Company's website at: www.htdsotc.com.
According to HTTD, "Shinn's attempts have been futile in accessing any of HTTD's confidential information regarding the Company's research plans, testing results or provisional patent information. The appropriate motions have been filed by HTTD's attorneys with the courts in Oklahoma and Colorado in order to enlighten the courts of Shinn's intentions of stealing HTTD's assets and attempting to circumvent the authority of the courts in other jurisdictions. Shareholders will be kept informed."
Mediation is still an option regarding the potential settlement of the appeal and securing the rights to Tubercin. The Company's position grows stronger each day in relation to benefiting patients and increasing shareholder value.
HTTD's CEO Colm King states, "HTTD's provisional patent will be enhanced this month. Additional patent information and updates on the Company's negotiations with a major drug firm will be available within the next 30 days."
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
posted
Hard To Treat Diseases, Incorporated Announces: Motion for Summary Judgment Filed in Oklahoma
DELRAY BEACH, FL, Mar 17, 2006 (MARKET WIRE via COMTEX) -- Hard To Treat Diseases, Incorporated (HTTD) (HTDS : hard to treat diseases inc com
HTDS0.00, 0.00, -8.0%) announces that a Motion For Summary Judgment was filed yesterday on its behalf in the District Court of Oklahoma County. The Motion makes the following facts abundantly clear: 1) HTTD is the lawful owner of the Tubercin substance in its possession and testing results performed on behalf of HTTD, 2) Shinn and his affiliated companies are keenly aware that they have no legal claim or rights to HTTD's Tubercin substance or testing results. The Motion For Summary Judgment with exhibits will be posted on HTTD's website at www.htdsotc.com as soon as they are available. HTTD's CEO Colm J. King states, "Shareholders will be kept informed on this matter and the progress of the Company's drug testing and related patents filed." Cautionary Note Regarding Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard To Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. CONTACT: Colm J. King CEO (561) 278-7856 Hard to Treat Diseases, Incorporated www.htdsotc.com SOURCE: Hard To Treat Diseases, Inc. http://www.htdsotc.com Copyright 2006 Market Wire, All rights reserved.
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
posted
Hard To Treat Diseases, Incorporated Announces: HTTD Featured on MacReport.Net Friday April 21, 8:00 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Apr 21, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that CEO Colm J. King and HTTD are featured on the MacReport.Net, a leading provider of online business and financial information. "The MacReport.Net is a powerful tool that will allow HTTD to increase its presence with investors and the Wall Street community," stated Mr. King. Mr. King noted, "The ability to get information out to our shareholders and to new potential investors is paramount. This opportunity allows shareholders and investors not only to read about HTTD but truly connect with us by seeing and hearing who we are and what HTTD's goals are. This technology has taken HTTD's ability to distribute information to an exciting new level." To listen to Mr. King's presentation go to the following link: http://www.publiccoreport.net/featured/HTDS/company.asp.
Additional information is available on the Company's website at: www.htdsotc.com. Existing shareholders or potential investors can track news and updates on HTTD by registering online at www.macreport.net. Registered users can also submit requests for additional information or ask questions regarding HTTD or any member company through the MacReport.Net site.
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
posted
Hard To Treat Diseases, Incorporated Announces: Details of Patent Application Relating to Viral Infections Tuesday May 2, 8:00 am ET
DELRAY BEACH, FLORIDA--(MARKET WIRE)--May 2, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces the Company's patent application relating to viral infections will be available on the United States Patent and Trademark Office's ("USPTO") website in June 2006.
In December 2004, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Viral Infections. This application provides a novel method for inhibition of viral infections and to the therapeutic treatment of diseases or disorders caused by such viral infections. The application became a utility patent application in December 2005. It will be available by the USPTO in full for review in June 2006 and scheduled for examination.
Two substances listed in the application, Tubercin (T-5) and Specific Substance of Maruyama ("SSM"), were acquired by HTTD for testing. The rights to the composition, Tubercin (T-5), are owned by Dr. Chung of South Korea, the inventor and patent holder. Dr. Chung has licensed the rights to Tubercin (T-5) for the use in medical care of cancer to another party. SSM was developed and advanced by Zeria Pharmaceutical Co., Ltd. ("Zeria") of Japan. This drug was also called Z-100 for clinical trials and is currently trade named Ancer 20. Zeria is currently using Ancer 20 injection for radiotherapy-induced leukopenia. The composition patent for this drug has been abandoned and is no longer protected by patent.
HTTD's CEO, Colm J. King, has met with both Dr. Chung in South Korea and with the President of Zeria USA, Inc. regarding the advancement of HTTD's patent applications.
The above utility application is one of two patent applications currently being packaged for presentation to major drug companies. Pharmaceutical companies that specialize in oncology and infectious diseases are the targeted candidates for the acquisition of HTTD's patent rights, testing and research. Additional testing by HTTD is not required for our presentation, but the Companies medical advisors and researchers have prepared protocols for additional testing that will enhance HTTD's current applications and potentially lead to new patent applications for the treatment of other diseases.
posted
Hard To Treat Diseases, Incorporated Announces: Details of Patent Application Relating to Cancer Tuesday May 9, 8:00 am ET
DELRAY BEACH, FLORIDA--(MARKET WIRE)--May 9, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces the Company's patent application relating to cancer is the second of two patent applications that the Company filed, owns and controls.
In December 2005, HTTD filed a provisional patent application for Methods and Compositions for Treatment of Cancer. This application provides a novel method for inhibition and prevention of cancer, to the diseases associated with such cancers and to the therapeutic treatment of diseases or disorders caused by such cancers. This application will became a utility patent application in December 2006.
HTTD's patent applications are the result of testing conducted on two substances; Tubercin (T-5) and Specific Substance of Maruyama ("SSM"). Please refer to the Company's press release dated May 2, 2006 titled "Details of Patent Application Relating to Viral Infections" for additional information on these substances.
Tubercin (T-5), SSM or a functional derivative thereof can be used for treatment, as stated in the abstracts of HTTD's patent applications. SSM is the substance that the Company will be presenting to pharmaceutical companies for acquisition regarding HTTD's applications. Regardless of whether HTTD acquires marketing rights to Tubercin (T-5), HTTD solely owns and controls utility patent rights to the drug.
The Company is aggressively moving forward and advancing its position with the rights owned that are unencumbered, as opposed to waiting to secure rights that may be unnecessary.
The above application is one of two patent applications currently being packaged for presentation to major drug companies. Pharmaceutical companies that specialize in oncology and infectious diseases are the targeted candidates for the acquisition of HTTD's patent rights, testing and research. Protocols for additional testing that potentially may lead to new patent applications for the treatment of other diseases are included in the presentation to drug companies.
posted
Hard To Treat Diseases, Incorporated Announces: Involvement of Dr. Leland Shapiro Wednesday May 17, 9:35 am ET
DELRAY BEACH, FL--(MARKET WIRE)--May 17, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that Dr. Leland Shapiro will be instrumental in the process of doing a deal with a major pharmaceutical company.
Dr. Shapiro has been the principal investigator for conducting the majority of experiments and lab research that culminated in HTTD's current patent applications and testing results. He has established protocols that define specific areas for additional testing that will be included in the presentations to drug companies.
The process of dealing with a pharmaceutical company involves numerous steps, including a presentation that explains substantiated findings and assets and face-to-face scientific meetings. Dr. Shapiro will be actively involved in both steps.
HTTD's CEO Colm J. King states, "Dr. Shapiro is an experienced medical and scientific research professional. He can discuss the testing results included in HTTD's patent applications, the detailed protocols he has established and the potential of the Company's patent rights better than any other individual. His involvement on the Company's expert team in discussing patent application discoveries and developments is a valuable asset."
The Company is aggressively moving forward by positioning its assets for acquisition by a major drug company that specializes in oncology and infectious diseases. An expert team is focused on the process of presentations and negotiations for the benefit of patients and shareholders.
posted
Hard To Treat Diseases, Incorporated Announces: Spin-Off of Cavit Sciences, Inc. Wednesday June 14, 8:00 am ET
DELRAY BEACH, FL--(MARKET WIRE)--Jun 14, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that the Company’s Board of Directors voted to spin-off its wholly-owned subsidiary, Cavit Sciences, Inc., to HTTD shareholders of record on June 13, 2006.
HTTD had previously assigned certain of its patent application rights and related assets to Cavit Sciences, Inc. (“Cavit”), a corporation formed as a wholly-owned subsidiary of HTTD. Cavit shares were issued to HTTD as consideration for the assets acquired by Cavit.
HTTD will distribute the Cavit shares as a stock dividend to the HTTD shareholders of record as of June 13, 2006. HTTD expects to pay the stock dividend on or about September 30, 2006.
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
